Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 52.40
Change Today +0.50 / 0.96%
Volume 658.0K
MDGS On Other Exchanges
Tel Aviv
As of 10:24 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

medigus ltd (MDGS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/14/15 - $58.90
52 Week Low
12/30/14 - $25.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDIGUS LTD (MDGS)

Related News

No related news articles were found.

medigus ltd (MDGS) Related Businessweek News

No Related Businessweek News Found

medigus ltd (MDGS) Details

Medigus Ltd., a medical device company, designs, develops, and sells endoscopic procedures and devices. The company offers Medigus Ultrasonic Surgical Endostapler system, an endoscope device comprising a surgical stapler, miniature camera, and an ultrasound sensor for incisionless treatment of gastroesophageal reflux disease. Medigus Ltd. was founded in 2000 and is headquartered in Omer, Israel.

Founded in 2000

medigus ltd (MDGS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 345.0K
Founder and Global Chief Operating Officer
Total Annual Compensation: 7.0K
Chief Financial Officer
Total Annual Compensation: 443.0K
Executive Vice President
Total Annual Compensation: 523.0K
Chief Technology Officer
Total Annual Compensation: 421.0K
Compensation as of Fiscal Year 2013.

medigus ltd (MDGS) Key Developments

Medigus Expects American Medical Association Publication of Category I Current Procedural Terminology Code for Esophagogastric Fundoplasty Trans-Orifice Procedures

Medigus Ltd. announced that the American Medical Association has created a new Category 1 Current Procedural Terminology code for Esophagogastric Fundoplasty Trans-Orifice Approach procedures which Medigus anticipates would be the code used for its MUSE(TM) platform. The AMA published its decision on March 9, 2015 following the submission of an application jointly sponsored by four key specialty medical societies: American Gastroenterological Association, American College of Gastroenterology, American Society for Gastrointestinal Endoscopy and the Society of American Gastrointestinal and Endoscopic Surgeons. The code, 432XX1, will enable physicians to specifically communicate information to payers about the procedure which is used to treat the underlying anatomical cause of chronic Gastroesophageal Reflux Disease. CPT codes are descriptive terms physicians use for reporting all medical, surgical, and diagnostic services and procedures; Category I codes are most frequently used by healthcare providers when reporting a significant portion of their services. In order to be granted a Category I code, an application must go through a rigorous sequential review and approval process by key members of the medical community who evaluate the procedure's value to physicians and patients. Following this approval, the recommendation will next be reviewed by the Relative Value Committee in April, which will further assess the value for physician payment levels under Medicare. Approvals are scheduled to be finalized in November, and the new code is expected to take effect on January 1, 2016.

MediGus Ltd. Presents at 27th Annual ROTH Conference, Mar-11-2015 10:00 AM

MediGus Ltd. Presents at 27th Annual ROTH Conference, Mar-11-2015 10:00 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Christopher Rowland, Chief Executive Officer and Director.

Medigus Announces Extension of Exclusive Distribution Agreement with Sinopharm in China

Medigus Ltd. announced an extension of its 2013 agreement with Sinopharm (China National Pharmaceutical Group Corporation) which granted the Chinese pharmaceutical company exclusive rights to distribute the MUSE(TM) system in China. Sinopharm has been granted up to two years from the date of the extension of the agreement to gain all necessary regulatory approvals from the China Food and Drug Administration (CFDA). The agreement extends Sinopharm's exclusivity to distribute the MUSE system from two to four years following receipt of such regulatory approvals, and Sinopharm has also committed to purchasing a minimum of $17.6 million worth of MUSE and related products over the course of four years, from the date of CFDA approval. Medigus will receive an upfront deposit of $350,000 towards initial purchase of MUSE systems, which will be returned by Medigus (less any amounts for products ordered) if the regulatory approval is not achieved during the timeframe specified in the agreement. The agreement also provides Sinopharm with the discretionary right to appoint Golden Grand Medical (Shanghai Golden Grand-Medical Instruments Ltd.), a Chinese company specializing in the distribution of medical devices, as its exclusive sub-distributor in China. Under the agreement, Golden will manage sales and customer service, marketing and training, and recording of clinical trials, following submittal of non-compete clauses and intellectual property protection, and other, similar restrictions, while Sinopharm remains solely responsible towards Medigus under the agreement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGS:IT 52.40 +0.50

MDGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGS.
View Industry Companies

Industry Analysis


Industry Average

Valuation MDGS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGUS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at